- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
Myh6 CreERT2 Mouse Model
| Strain Name | Myh6 CreERT2 Mouse Model (M02116) |
|---|---|
| Editing Type | Transgenic |
| Gene Name | Myh6 (myosin, heavy polypeptide 6, cardiac muscle, alpha; protein myosin-6 / α-MHC; human ortholog MYH6) |
| Gene Synonyms | Myhca; Myhc-a; alphaMHC; alpha-MHC; A830009F23Rik |
| Strain Background | C57BL/6N |
| NCBI No. | Gene ID 17888 |

- Cardiac gene function studies — Cross to Floxed lines for conditional deletion or activation in cardiomyocytes, then read out the gene’s role in cardiac development, homeostasis, hypertrophy, heart failure and arrhythmia.
- Cardiomyocyte lineage tracing — Paired with a LoxP-STOP reporter, a tamoxifen pulse at a chosen time point labels cardiomyocytes and their progeny, letting you follow proliferation, differentiation and fate through injury, repair or regeneration.
- Cardiac disease modeling & target validation — Generate cardiomyocyte-specific genetic models that recapitulate human cardiac disease, and use them to test gene therapy or pharmacological intervention.
- Time-windowed intervention — Recombination is tamoxifen-gated rather than constitutive, so the model fits experiments where when the gene is lost matters as much as the loss itself.
- Disease-anchored ortholog — Human MYH6 is NCBI-annotated as implicated in atrial septal defect, heart conduction disease and intrinsic cardiomyopathy; mouse Myh6 variants are used to model dilated and hypertrophic cardiomyopathy.
This strain drives CreERT2 from the cardiomyocyte α-myosin heavy chain (Myh6) promoter, delivered either as a transgene or by knock-in. CreERT2 fuses Cre recombinase to a mutated estrogen receptor ligand-binding domain: without tamoxifen it remains cytoplasmic, and on tamoxifen administration it translocates to the nucleus and recombines LoxP sites. Crossing to a Floxed line therefore produces conditional, time-controlled deletion, activation or reporter expression in cardiomyocytes — at a chosen developmental stage or in adulthood. Because the Myh6 promoter carries some of the most cardiac-restricted activity in the mouse genome (adult heart RPKM 1317.1, with no other tissue approaching it), the driver localizes recombination to the myocardium without a tissue-specific Cre having to be engineered per target gene.
- Driver specificity backed by the gene’s own expression profile — NCBI annotates Myh6 as restricted toward adult heart at RPKM 1317.1, far above any other tissue; the cardiac localization rests on measured expression, not on a promoter claim alone.
- Spatial and temporal control in one strain — CreERT2 is held in the cytoplasm until tamoxifen is given, so deletion can be switched on after development is complete or at any chosen disease stage. A constitutive αMHC-Cre cannot offer that window.
- One driver, any Floxed allele — Conditional knockout, conditional activation and reporter readouts all run off the same colony, so a single line supports multiple projects without building a new Cre per target.
- Purpose-built for fate mapping — With a LoxP-STOP reporter, timed tamoxifen pulses mark cardiomyocytes and their descendants, enabling proliferation and fate analysis in injury, repair and regeneration paradigms.
- Deep cardiac literature behind the ortholog — Human MYH6 is linked by NCBI to septal defects, conduction disease and intrinsic cardiomyopathy; 358 PubMed citations and 25 GeneRIFs support cardiac disease modeling on this background.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.
